Mulugeta Mamo
Novartis (Switzerland)(CH)Novartis (China)(CN)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
Neurological diseases and metabolism, RNA regulation and disease, Synthesis and biological activity, Melanoma and MAPK Pathways, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo(2005)244 cited
- → Syntheses of Potent, Selective, and Orally Bioavailable Indazole-Pyridine Series of Protein Kinase B/Akt Inhibitors with Reduced Hypotension(2007)62 cited
- → Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt(2007)62 cited
- → Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers(2017)44 cited
- → Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors(2017)40 cited
- → Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design(2018)39 cited
- → Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic(2019)38 cited
- → Facilitating unambiguous NMR assignments and enabling higher probe density through selective labeling of all methyl containing amino acids(2016)34 cited
- → Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity(2018)33 cited
- → 2-Pyridyl P1′-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors (A-792611 and A-790742) with Potential for Convenient Dosing and Reduced Side Effects(2009)30 cited